Chemotherapy use in stage III colon cancer: A National Cancer Database analysis

Smrity Upadhyay, Sumit Dahal, Vijaya Raj Bhatt, Nabin Khanal, Peter T. Silberstein

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Although adjuvant chemotherapy in stage III colon cancer improves overall survival, prior studies have shown that it is underused. We analyzed different factors that may influence its use. Methods: This is a retrospective study of stage III colon cancer patients (n = 207,718) diagnosed between 2000 and 2011 in the National Cancer Data Base (NCDB). The NCDB contains ∼70% of new cancer diagnosis from >1500 American College of Surgeons accredited cancer programs in the United States and Puerto Rico. The chi-squared test was used to determine any difference in characteristics of patients who did or did not receive chemotherapy. Results: A total of 35% of all stage III colon cancer patients, and 38% of stage III cases undergoing surgery, did not receive adjuvant chemotherapy. The use of chemotherapy had increased in recent years (64% in 2007-2011 versus 59% in 2000-2002; p <0.0001). Its use was lower in whites (61%), females (60%), patients ≥3/460 years (55%), patients with one or more comorbidities (55%), nonacademic centers (62%), those with medicare insurance (52%), lower education (61%) and income levels (59%, all p <0.0001). The nonwhite and uninsured were more likely to be

Original languageEnglish
Pages (from-to)244-251
Number of pages8
JournalTherapeutic Advances in Medical Oncology
Volume7
Issue number5
DOIs
StatePublished - Sep 24 2015

Fingerprint

Colonic Neoplasms
Databases
Drug Therapy
Neoplasms
Adjuvant Chemotherapy
Puerto Rico
Medicare
Insurance
Comorbidity
Retrospective Studies
Education
Survival

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Chemotherapy use in stage III colon cancer : A National Cancer Database analysis. / Upadhyay, Smrity; Dahal, Sumit; Bhatt, Vijaya Raj; Khanal, Nabin; Silberstein, Peter T.

In: Therapeutic Advances in Medical Oncology, Vol. 7, No. 5, 24.09.2015, p. 244-251.

Research output: Contribution to journalArticle

Upadhyay, Smrity ; Dahal, Sumit ; Bhatt, Vijaya Raj ; Khanal, Nabin ; Silberstein, Peter T. / Chemotherapy use in stage III colon cancer : A National Cancer Database analysis. In: Therapeutic Advances in Medical Oncology. 2015 ; Vol. 7, No. 5. pp. 244-251.
@article{419c69a0d77b40fc947422c1effcd026,
title = "Chemotherapy use in stage III colon cancer: A National Cancer Database analysis",
abstract = "Background: Although adjuvant chemotherapy in stage III colon cancer improves overall survival, prior studies have shown that it is underused. We analyzed different factors that may influence its use. Methods: This is a retrospective study of stage III colon cancer patients (n = 207,718) diagnosed between 2000 and 2011 in the National Cancer Data Base (NCDB). The NCDB contains ∼70{\%} of new cancer diagnosis from >1500 American College of Surgeons accredited cancer programs in the United States and Puerto Rico. The chi-squared test was used to determine any difference in characteristics of patients who did or did not receive chemotherapy. Results: A total of 35{\%} of all stage III colon cancer patients, and 38{\%} of stage III cases undergoing surgery, did not receive adjuvant chemotherapy. The use of chemotherapy had increased in recent years (64{\%} in 2007-2011 versus 59{\%} in 2000-2002; p <0.0001). Its use was lower in whites (61{\%}), females (60{\%}), patients ≥3/460 years (55{\%}), patients with one or more comorbidities (55{\%}), nonacademic centers (62{\%}), those with medicare insurance (52{\%}), lower education (61{\%}) and income levels (59{\%}, all p <0.0001). The nonwhite and uninsured were more likely to be",
author = "Smrity Upadhyay and Sumit Dahal and Bhatt, {Vijaya Raj} and Nabin Khanal and Silberstein, {Peter T.}",
year = "2015",
month = "9",
day = "24",
doi = "10.1177/1758834015587867",
language = "English",
volume = "7",
pages = "244--251",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Chemotherapy use in stage III colon cancer

T2 - A National Cancer Database analysis

AU - Upadhyay, Smrity

AU - Dahal, Sumit

AU - Bhatt, Vijaya Raj

AU - Khanal, Nabin

AU - Silberstein, Peter T.

PY - 2015/9/24

Y1 - 2015/9/24

N2 - Background: Although adjuvant chemotherapy in stage III colon cancer improves overall survival, prior studies have shown that it is underused. We analyzed different factors that may influence its use. Methods: This is a retrospective study of stage III colon cancer patients (n = 207,718) diagnosed between 2000 and 2011 in the National Cancer Data Base (NCDB). The NCDB contains ∼70% of new cancer diagnosis from >1500 American College of Surgeons accredited cancer programs in the United States and Puerto Rico. The chi-squared test was used to determine any difference in characteristics of patients who did or did not receive chemotherapy. Results: A total of 35% of all stage III colon cancer patients, and 38% of stage III cases undergoing surgery, did not receive adjuvant chemotherapy. The use of chemotherapy had increased in recent years (64% in 2007-2011 versus 59% in 2000-2002; p <0.0001). Its use was lower in whites (61%), females (60%), patients ≥3/460 years (55%), patients with one or more comorbidities (55%), nonacademic centers (62%), those with medicare insurance (52%), lower education (61%) and income levels (59%, all p <0.0001). The nonwhite and uninsured were more likely to be

AB - Background: Although adjuvant chemotherapy in stage III colon cancer improves overall survival, prior studies have shown that it is underused. We analyzed different factors that may influence its use. Methods: This is a retrospective study of stage III colon cancer patients (n = 207,718) diagnosed between 2000 and 2011 in the National Cancer Data Base (NCDB). The NCDB contains ∼70% of new cancer diagnosis from >1500 American College of Surgeons accredited cancer programs in the United States and Puerto Rico. The chi-squared test was used to determine any difference in characteristics of patients who did or did not receive chemotherapy. Results: A total of 35% of all stage III colon cancer patients, and 38% of stage III cases undergoing surgery, did not receive adjuvant chemotherapy. The use of chemotherapy had increased in recent years (64% in 2007-2011 versus 59% in 2000-2002; p <0.0001). Its use was lower in whites (61%), females (60%), patients ≥3/460 years (55%), patients with one or more comorbidities (55%), nonacademic centers (62%), those with medicare insurance (52%), lower education (61%) and income levels (59%, all p <0.0001). The nonwhite and uninsured were more likely to be

UR - http://www.scopus.com/inward/record.url?scp=84940191842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940191842&partnerID=8YFLogxK

U2 - 10.1177/1758834015587867

DO - 10.1177/1758834015587867

M3 - Article

AN - SCOPUS:84940191842

VL - 7

SP - 244

EP - 251

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 5

ER -